UCSD Study Finds New Ovarian Cancer Treatment Possibilities

February 20, 2017 8:49 pm

Using a new insight into the nature of ovarian cancer, a team of UC San Diego scientists have found potential new drug targets.

The researchers discovered that existing drugs targeting autophagy were effective in drug-resistant human tumors grafted onto mice, … Read more

Murine Study Finds Potential Boost For Ovarian Cancer Drug Olaparib

February 1, 2017 8:12 pm

Researchers from the Chinese Academy of Sciences have discovered that the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) helps cancer cells repair their DNA and found that inhibiting PGAM1 sensitizes tumors to the cancer drug Olaparib (Lynparza). Their findings in the … Read more

Ovarian Cancer Clinical Trial Results: Data Points to Treatment Options Beyond Standard Chemotherapy

February 1, 2017 5:19 pm

By: Cory Bentley, PhD

Many women diagnosed with ovarian cancer could probably write a dissertation for an advanced degree on ovarian cancer. Whether women are newly diagnosed or have recurrent ovarian cancer, the new learning needed to make informed decisions

Read more

What’s the Best Chemotherapy Strategy in Ovarian Cancer?

January 30, 2017 9:41 pm

Results from the Gynecologic Oncology Group (GOG) 252 trial, while highly anticipated in the oncology community, did not give any additional clarity for the use of intravenous (IV) versus intraperitoneal (IP) chemotherapy for patients with ovarian cancer, says Franco M. … Read more

Report: 2016 State of the State of Gynecologic Cancers

January 25, 2017 8:04 pm

Today in celebration of its 25th anniversary, the Foundation for Women’s Cancer with the Society of Gynecologic Oncology released a comprehensive report on the most recent advances in the detection and treatment of gynecologic cancers.

The 2016 State of the Read more

More Chemo May Not Equal Better Outcomes in Ovarian Cancer

January 23, 2017 7:56 pm

Increasing the number of cycles of chemotherapy doesn’t appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.

The retrospective cohort study of 201 patients showed that recurrence and … Read more

Tesaro Opens Expanded Program of PARP inhibitor for U.S. Ovarian Cancer Patients

January 18, 2017 7:31 pm

Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more

Experts Forecast Cancer Research and Treatment Advances in 2017

January 17, 2017 7:09 pm

As we step into 2017, a big question looming in the minds of all stakeholders in the cancer research arena is: What is the future of cancer research in the new administration? Members of Congress on both sides of the … Read more

New Clinical Trial Combines Two Methods to Defeat Ovarian Cancer

January 12, 2017 3:31 am

Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, a cancer doctor at the UNM Comprehensive Cancer Center, hopes a new therapy that delivers a one-two punch to cancer cells will … Read more

In Ovarian Cancer Advancements, Finding New Biomarkers Is Key

January 5, 2017 9:02 pm

The search for validated, actionable biomarkers may be more important than initiating more phase 3 trials in the field of ovarian cancer, according to Maurie Markman, M.D.

“In the ovarian cancer arena, we have 30 years of history of doing … Read more

Gene Testing Could Help Predict Ovarian Cancer Patients’ Sensitivity

January 2, 2017 7:55 pm

Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.

Scientists found that defects in a gene called ARID1A caused … Read more

Drug Combo Promising in Recurrent Ovarian Cancer

December 27, 2016 8:07 pm

Heavily pre-treated patients with recurrent ovarian cancer have limited options when it comes to regimens that can control disease while maintaining a satisfactory quality of life.

Now, a phase II open-label study has demonstrated that a combination of the camptothecin … Read more